Autologous Dendritic Cell Vaccine in Kidney Cancer

The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.

Trial Details

NCT ID
NCT05127824
Phase
PHASE2
Sponsor
Jodi Maranchie
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Autologous alpha-DC1/TBVA vaccine
  • Cabozantinib
Locations (sample)
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Histologically proven clear cell renal cancer that is non-metastatic and amenable to surgical resection with no evidence of metastatic disease or l…
  • 18 years or older (male or female) with an ECOG performance status of 0 or 1.
  • Have serotype HLA-A2+ if receiving vaccine.
  • Capable of understanding and complying with the protocol requirements and have signed the informed consent document.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →